Howe Sound Research TECHPBA 325 Proteomic Biomarker Analytics
Specifications
- Product Name: Proteomic Biomarker Analytics
- Edition: 2nd Edition
- Markets: Forecasts by Application, Technology, Product, and Place
- Publisher: Howe Sound Research
- Based in: Vancouver, British Columbia, Canada
Product Usage Instructions
About the Product
The Proteomic Biomarker Analytics product is a market research report focusing on scientific industries, particularly Biotechnology and Clinical Diagnostic markets. It provides insights and forecasts on various aspects of proteomic biomarker analytics.
How to Access the Report
To access the report, please contact Howe Sound Research at the provided email address for licensing options. Once you have the necessary license, you can securely access and view the report.
Intellectual Property Protection
This document contains copyrighted intellectual property. Respect the terms of your license and do not circulate, copy, quote, or reproduce any part of the report without approval from Howe Sound Research.
- Proteomic Biomarker Analytics Market size was valued at US$24,983.8 million in 2023 and is poised to grow at a CAGR of 9.1% from 2024-2030. Proteomic biomarkers are proteins that detect the presence of certain illnesses or processes. They serve as quantitative markers of normal biological processes, pathogenic processes, or pharmacologic responses to treatments, such as tumour detection and treatment. This technology has the potential to replace Genomics and become the centre point of therapeutic applications. As we have discussed, its potential application is a huge opportunity for companies to tap into. Developments in Protein Biomarkers give a huge potential to companies to expand in disease diagnostics, etc.
- The increasing incidence of chronic illnesses, growing demand for personalized medicines, increasing R&D expenditure, and advancement of diagnostic techniques are driving the growth of the proteomics industry. The rising frequency of chronic illnesses such as cardiovascular diseases, respiratory diseases, and especially cancer has increased the need for an effective diagnostic method. Furthermore, the increasing use of proteomics in drug discovery and development has greatly boosted market growth. The main restraints for this market are the lack of skilled workers who have expertise in proteomic research, cost, and the huge requirement of resources, infrastructure needed for the research. There are regulatory norms that are also very stringent and act as restraints. COVID-19 was a push for the Proteomic biomarker analytics market, as most of the companies and research institutes invested in proteomic technology to find the relevant biomarkers for COVID-19.
Key Developments
- In January 2024, Vector Laboratories and Navinci Diagnostics announced a strategic collaboration to develop novel spatial proteomic tools for biomarker discovery, with product launches scheduled for 2025
- In August 2022, Bruker Corporation launched the new nanoElute 2 nano-LC, of MetaboScape and TASQ 2023 software supporting fluxomics, and with the latest advances in PaSER intelligent acquisition to enhance research in protein-protein interactions (PPIs) and metaproteomics applications.
Proteomic Biomarker Analytics Market Summary
Proteomic Biomarker Analytics Market Dynamics
- Drug discovery sees a trend of using proteomic technology, and the finding of disease-specific biomarkers signifies the rise of the use of biomarkers in diagnostics. Major companies are investing huge in technologies for the discovery of biomarkers, such as Mass spectrometry and protein microarrays. The main research topic in this market is the early diagnostics of cancer. All these factors addition to the advancement of healthcare, give an upside drive to the market. There are hundreds of clinical trials of protein biomarkers only for cancer, which indicates the involvement of companies in research.
- From this we can conclude that the demand for the new and existing Proteomic Biomarkers will be rising and this helps the market to expand. Companies like Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., GE Healthcare, Illumina, Inc., Merck, Thermo Fisher Scientific holds a substantial share of the Proteomic biomarker analytics market.
North America Got a Significant Share
Proteomic Biomarker Analytics Market Regional Analysis
- North America dominates the Global Proteomic biomarker analytics market and is expected to dominate in the forecasted years because of its advanced infrastructure and increased ability to spend on research. The National Institutes of Health (NIH) of the U.S. provided $37 billion for biomedical research, which also includes Proteomic Biomarker Identification.
- Germany is the lucrative and most dynamic market in Europe, which contributes significant share in the Europe Proteomic biomarker analytics market. In Asia Pacific, Japan is the dominant player of the Proteomic biomarker analytics market which holds more than half of the market share.
Proteomic Biomarker Analytics Market Segmentation Analysis
Report Overview Table
| Category | Details |
|---|---|
| Report Study Period | 2025–2031 |
| Market Size (2023) | US$ 24,983.8 million |
| Market CAGR | 9.1% |
| Applications |
|---|
| Drug Discovery |
| Research Application (Cancer) |
| Clinical Diagnostics |
| Other |
By Technology
| Technologies |
|---|
| Mass Spectrometry |
| ELISA/Beads |
| Hybrid Multiplex |
| X-ray Crystallography |
| Electrophoresis |
| Microarray |
| Other |
By End User
| End Users |
|---|
| Academic and Research Institutions |
| Pharma/Biotech Companies |
| Clinical Diagnostic Laboratories |
| Other |
By Region
| Regions |
|---|
| North America |
| Europe |
| Asia Pacific |
| Middle East and Africa |
| Latin America |
Key Features of the Report
- The report provides granular-level information about the market size, regional market share, historic market (2020-2024), and forecast (2025-2031).
- The report covers in-depth insights about the competitor’s overview, company share analysis, key market developments, and their key strategies.
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market.
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market.
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenarios.
- The report analyses the impact of the socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis.
FAQs
What is the proteomic biomarker analytics market size and expected growth rate?
Proteomic biomarker analytics market size was valued at IJS$24,983.8 million in 2023 and is poised to grow at a CAGR of 9.1% from 2024-2030.
Who are the key players in the market?
The key players in the proteomic biomarker analytics market, Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., GE Healthcare, Illumina, Inc., Merck, and Thermo Fisher Scientific hold a substantial share of the Proteomic biomarker analytics market.
What are the factors driving the market?
The increasing incidence of chronic illnesses, mainly cancer, the growing demand for personalized medicines, increasing R&D expenditure, and the advancement of diagnostic techniques are driving the growth of the proteomics industry.
Documents / Resources
 |
Howe Sound Research TECHPBA 325 Proteomic Biomarker Analytics [pdf] User Guide TECHPBA 325, TECHPBA 325 Proteomic Biomarker Analytics, TECHPBA 325, Proteomic Biomarker Analytics, Biomarker Analytics, Analytics |